Butirrisan® for IBS-D: targeted microbiota support with clinically backed outcomes

Diarrhea-predominant IBS (IBS-D) is linked to dysbiosis and reduced butyrate producers. In a pragmatic, 8-week interventional study (n=205), Clostridium butyricum CBM588® (Butirrisan®) was associated with significant improvements in diarrhea episodes, stool frequency, Bristol stool score, IBS-SSS, and QoL, with high adherence and favorable tolerability. These real-life findings support routine integration alongside dietary guidance.

Reframing IBS-D: from motility to mucosal ecology

IBS-D remains a daily burden for patients and a therapeutic challenge for clinicians. Beyond antispasmodics, there is growing interest in restoring eubiosis and butyrate production—core deficits observed in IBS-D.

Butyrate fuels colonocytes, supports barrier integrity, modulates mucosal immunity, and influences water/sodium reabsorption—mechanisms directly relevant to diarrhea control. Re-introducing butyrate producers is therefore a rational, clinically meaningful target, aligning microbial shifts with symptom improvement.

Introducing Butirrisan®

Butirrisan® is a dietary supplement delivered as tiny tablets (pack size: 90), featuring the single-strain probiotic Clostridium butyricum CBM588® (≥4.5×10^5 CFU/tablet) and its recommended intake is 3 tablets/day for 8 weeks, typically with breakfast; tablets may be taken in a single administration are easy to swallow.

What sets the CBM588® strain apart:

Endogenous, continuous butyrate production via buk and but pathways; supports tight-junction expression.
Spore-forming, oxygen-tolerant strain delivering room-temperature stability and suitability during antibiotic therapy (spores are naturally resilient).
“Next-generation” precision probiotic for IBS-D routines with strong ease-of-use.

Clinical signals at a glance

A recently published, peer-reviewed, prospective real-life interventional study in Microorganisms (2025) evaluated 8 weeks of Butirrisan® supplementation in adults with IBS-D (n=205), with outcomes on stool form/frequency, diarrhea episodes, IBS-SSS, QoL, and a microbiota sub-analysis; a retrospective standard-care cohort (n=200; trimebutine maleate plus other probiotics) provided contextual comparison.

Design/Population/Duration: Prospective, real-life, monocentric interventional study; total N=405 adults with IBS-D (Rome IV). Butirrisan® cohort n=205 (3 tablets/day for 8 weeks, low-fiber/low-residue diet) vs comparator cohort n=200 (trimebutine + other probiotics, same diet); 8 weeks.
Endpoints: Diarrhea episodes/day; stool frequency/day; Bristol Stool Scale (BSS 6–7 prevalence); IBS-SSS; bloating; bowel dissatisfaction; quality of life (QoL). Microbiota sub-analysis in a random subset.

Key results (Butirrisan® cohort):
- BSS 6–7 prevalence: −90% at 8 weeks
- Stool frequency: −57%
- Diarrhea episodes/day: −85%
- IBS-SSS: −56%
- Bloating: −53%
- Bowel dissatisfaction: −48%
- QoL: +52%
- Microbiota (n=19): α-diversity +21% (p=0.008) with enrichment of butyrate-producing genera correlating with symptom gains.

Translating data into daily practice

Butirrisan® offers a clinically backed option to support IBS-D management in real-life outpatient settings, alongside dietary guidance and standard care. Consider it for adults with frequent loose stools (BSS Types 6–7), urgency, and bloating where a butyrate-producer may help re-establish eubiosis. The pragmatic design, strong adherence, and easy regimen make integration straightforward across pharmacy and gastroenterology channels

If you’re a distributor, this is a timely opportunity to explore Butirrisan® for your portfolio—its targeted mechanism, practical 3-tablet/day regimen, and real-world evidence make it a compelling addition.